SLNO - NASDAQ
Soleno Therapeutics, Inc.
$53.01
+0.038%Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
At a Glance
Live Snapshotslno
Total Payables
Last Annual Value
12.44M
3-Year CAGR
91%
5-Year CAGR
29%
10-Year CAGR
38%
Soleno Therapeutics, Inc. Competitors Analysis of Total Payables
| Company | Total Payables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Soleno Therapeutics, Inc. NASDAQ:SLNO | 12.44M | 58.1% | 30.8% | 40.6% | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 31.00M | -9.7% | 12.6% | 19.2% | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 8.08M | -29.4% | 14.9% | -31.0% | |
 Celcuity Inc. NASDAQ:CELC | 6.41M | 8.1% | 33.6% | 34.5% | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 24.63M | 61.8% | 18.0% | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 53.25M | 92.1% | 105.8% | 46.1% | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 1.22M | -17.1% | N/A | N/A | |
 Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 9.61M | -12.1% | -0.3% | N/A |
Soleno Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your SLNO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.